1586033-68-2

Upstream product

• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 1586033-65-9 N-(α-methyl-4-iodobenzyl)-N-formylglycine methyl ester 
• 439811-16-2 C₁₀H₉F₃INO 
• 1586033-67-1 N-(α-methyl-4-iodobenzyl)-N-formyl-C-formylglycine methyl ester 
• 333-20-0 potassium thioacyanate 
• 1586033-63-7 N-(α-methyl-4-iodobenzyl)glycine methyl ester 
• 150085-44-2 R-(+)-1-(4-iodophenyl)ethylamine 

Downstream Products

• 813466-05-6 (R)-(+)-methyl 1-[1-(4-iodophenyl)ethyl]-1H-imidazole-5-carboxylate 
• 1586033-71-7 (R)-1-[1-(4-trimethylstannylphenyl)ethyl]-1H-imidazole-5-carboxylic acid ethylmethylamide 
• 1588490-10-1 (R)-1-[1-(4-trimethylstannylphenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinylamide 
• 1588490-09-8 (R)-1-[1-(4-iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinylamide 

Relevant academic research and scientific papers

Radiopharmaceutical products for diagnosis and therapy of renal carcinoma

A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic

RADIOPHARMACEUTICAL PRODUCTS FOR DIAGNOSIS AND THERAPY OF ADRENAL CARCINOMA

A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic